MTEM
NASDAQMolecular Templates Inc.
Latest news
25 items- PRCalidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational HighlightsBolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025
- PRCalidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and DirectorSAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa
- SECSEC Form 8-K filed by Molecular Templates Inc.8-K - Molecular Templates, Inc. (0001183765) (Filer)
- SECSEC Form 8-K filed by Molecular Templates Inc.8-K - Molecular Templates, Inc. (0001183765) (Filer)
- PRMolecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing RulesAUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or the "Company")), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, was notified on December 16, 2024 by the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") of the Staff's determination pursuant to Nasdaq Listing Rule 5101 that the Company is a "public shell," and that, in the view of the Staff, the continued listing of the
- SECSEC Form DEFA14A filed by Molecular Templates Inc.DEFA14A - Molecular Templates, Inc. (0001183765) (Filer)
- SECSEC Form 8-K filed by Molecular Templates Inc.8-K - Molecular Templates, Inc. (0001183765) (Filer)
- SECSEC Form 8-K filed by Molecular Templates Inc.8-K - Molecular Templates, Inc. (0001183765) (Filer)
- PRMolecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price RequirementsAUSTIN, Texas, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or the "Company")), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announced that it has received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on November 25, 2024. The notice indicated that MTEM is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") as a result of
- SECSEC Form DEFA14A filed by Molecular Templates Inc.DEFA14A - Molecular Templates, Inc. (0001183765) (Filer)
- SECMolecular Templates Inc. filed SEC Form 8-K: Other Events8-K - Molecular Templates, Inc. (0001183765) (Filer)
- 13D/GAmendment: SEC Form SC 13G/A filed by Molecular Templates Inc.SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)
- INSIDERLarge owner Biotech Target N V sold $845,833 worth of shares (1,279,820 units at $0.66), closing all direct ownership in the company (SEC Form 4)4 - Molecular Templates, Inc. (0001183765) (Issuer)
- SECSEC Form NT 10-Q filed by Molecular Templates Inc.NT 10-Q - Molecular Templates, Inc. (0001183765) (Filer)
- 13D/GAmendment: SEC Form SC 13G/A filed by Molecular Templates Inc.SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)
- 13D/GAmendment: SEC Form SC 13G/A filed by Molecular Templates Inc.SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)
- SECSEC Form DEF 14A filed by Molecular Templates Inc.DEF 14A - Molecular Templates, Inc. (0001183765) (Filer)
- SECSEC Form PRE 14A filed by Molecular Templates Inc.PRE 14A - Molecular Templates, Inc. (0001183765) (Filer)
- SECSEC Form 8-K filed by Molecular Templates Inc.8-K - Molecular Templates, Inc. (0001183765) (Filer)
- SECSEC Form 8-K filed by Molecular Templates Inc.8-K - Molecular Templates, Inc. (0001183765) (Filer)
- INSIDERSEC Form 4 filed by Director Lalande Kevin M.4 - Molecular Templates, Inc. (0001183765) (Issuer)
- INSIDERSEC Form 4 filed by Director Gruia Gabriela4 - Molecular Templates, Inc. (0001183765) (Issuer)
- INSIDERSEC Form 4 filed by Director Selick Harold E4 - Molecular Templates, Inc. (0001183765) (Issuer)
- INSIDERSEC Form 4 filed by Director Hoffmann Dave4 - Molecular Templates, Inc. (0001183765) (Issuer)
- INSIDERSEC Form 4 filed by Director Sanders Corazon (Corsee) D.4 - Molecular Templates, Inc. (0001183765) (Issuer)
MTEM FAQ
6 questionsWhat does Molecular Templates Inc. do?
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; TAK-169 targeting CD38 is in Phase I clinical...Where does MTEM stock trade?
Molecular Templates Inc. (MTEM) is listed on NASDAQ.What sector and industry is MTEM in?
Molecular Templates Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Molecular Templates Inc. go public?
Molecular Templates Inc. (MTEM) completed its IPO in 2005.What companies are similar to MTEM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MTEM side-by-side with any of them on Quantisnow.How can I track MTEM on Quantisnow?
Quantisnow aggregates Molecular Templates Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MTEM to receive live email and push alerts on every new disclosure.